Topical ophthalmic β blockers may cause release of histamine through cytotoxic effects on inflammatory cells

Luc M van Beek, Marcel Mulder, Nicolaas J van Haeringen, Aize Kijlstra

Abstract

Aim—To evaluate the effects of β blockers used in ophthalmology on the release of histamine from mixed cell preparations containing human leucocytes and basophils.

Methods—A mixed leucocyte and basophil preparation was obtained from venous blood of healthy non-atopic volunteers. Cell preparations were then incubated with betaxolol, metipranolol, timolol, or carteolol. After incubation for 1 hour the histamine content of the supernatant was analysed by automated flurometric analysis. Cell viability was tested by measuring lactate dehydrogenase (LDH) concentrations.

Results—Betaxolol and metipranolol in concentrations between 10⁻⁶ M and 10⁻³ M liberated histamine from human blood cells in a dose dependent manner. Carteolol and timolol had no effect on histamine at these concentrations. At the same concentrations LDH was also detected in the supernatants of cell suspensions incubated with metipranolol or betaxolol.

Conclusions—Betaxolol and metipranolol induce substantial histamine release from human leucocytes, probably as a result of their cytotoxic effect.

Materials and methods

Isolation of leucocytes

Blood samples from healthy volunteers were collected in citrate tubes and suspended in an ice cold hypotonic ammonium chloride buffer, causing lysis of erythrocytes. The leucocytes were then washed twice with ice cold HEPES buffer containing 132 mM NaCl, 6 mM KCl, 1 mM CaCl₂, 1 mM MgSO₄, 1.2 mM K, 20 mM N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid (Sigma Chemical Co, St Louis, MO, USA), 5.5 mM glucose, and 0.5% (w/v) human serum albumin, pH 7.4, osmolality 280–300 mOsm/l. After washing the leucocytes were suspended in HEPES buffer and incubated with various β blockers.

The volunteers (n = 14) were free of atopic disease and were not taking any medication. Several different concentrations (usually three) of β blockers were tested in duplicate on each blood sample. All volunteers gave their informed consent and the study conformed to the Universal Declaration of Human Rights and to the European Convention for the Protection of Human Rights and Fundamental Freedoms.

The number of leucocytes per aliquot ranged from 46.2 × 10⁶ to 73.5 × 10⁶. Approxi-
mately 0.5% of leucocytes are basophils, giving a number of approximately 23.1–36.7 × 10^6 basophils per aliquot. The leucocytes were divided into aliquots of 250 µl to which 50 µl of a β blocker solution or phosphate buffered saline (control) was added (final volume 300 µl). The aliquots were then incubated for 1 hour at 37°C. After incubation the leucocytes were centrifuged (500 g) at room temperature and the supernatant was analysed for lactate dehydrogenase (LDH) or histamine.

In some experiments the viability of the cells was tested using trypan blue staining. Also, in some experiments cell pellets were resuspended after incubation and the cells were counted again. For the staining procedure cells were diluted 1:10 in trypan blue solution 0.3% in phosphate buffered saline. Cells were counted using phase contrast microscopy (Leica 090-131.001).

**HISTAMINE ASSAY**

Perchloric acid to a final concentration of 2% was added to 250 µl of the supernatant of incubated cell suspensions. The supernatants were then stored at 4°C until analysis (maximum 60 days). The histamine content was determined at the department of allergy at the central laboratory of blood transfusion (Amsterdam) by an automated spectrofluorometric o-phthalaldehyde assay. Briefly, this method consists of extracting histamine and coupling it to o-phthalaldehyde. The fluorescence of this complex is then measured by a spectrofluorometer using an excitation wavelength of 355 nm and an emission wavelength of 450 nm. It is assumed that the measured fluorescence was proportional to the concentration of histamine.

Because the number of basophils and the amount of histamine vary between individuals, the histamine content was expressed as a percentage of the total histamine. Total histamine was obtained by adding perchloric acid (final concentration 2 mg/ml) to one aliquot of leucocytes in each blood sample to cause lysis of the cells. This aliquot was then centrifuged and histamine was determined using the method described above. Percentages were corrected for spontaneous release which was defined as the histamine content of the supernatant of the control sample. The results were discarded if spontaneous release exceeded 15%.

**LACTATE DEHYDROGENASE (LDH) ASSAY**

Directly after the incubation experiments the supernatant of incubated cell suspensions was analysed for LDH content. Supernatant (5 µl) was mixed with 200 µl substrate buffer in a 96 well flat bottom plate. The substrate buffer contained 3.8 mM Na_2PO_4, 1.9 mM KH_2PO_4, 7.9 µg/ml pyruvic acid, and 15.9 µg/ml NADH, pH 7.0. In this mixture LDH converts NADH to NAD at a rate determined by the amount of LDH present. Experiments were performed at room temperature. Each 96 well plate contained total, control, and tested β blocker concentrations in duplicate.

**Results**

Initially we tested four β blockers (carteolol, betaxolol, metipranolol, and timolol) for their ability to release histamine from isolated leucocytes. These β blockers are currently in use for the treatment of glaucoma. After incubation for 1 hour at a concentration of 0.01 M, betaxolol and metipranolol released 79% and 88%, respectively, of the total histamine content from the basophils. At the same concentration timolol released only 18% of the histamine and carteolol did not release any (Table 1).

We then constructed dose-response curves for betaxolol, metipranolol, and timolol which are shown in Figure 1. Metipranolol and betaxolol in concentrations between 10^−3 M and 10^−2 M liberated histamine in a dose dependent manner. Timolol liberated significantly less histamine than either of the other β blockers at the highest concentration (10^−2 M).

To explain these results we hypothesised that the histamine releasing effect could be either specific (that is, mediated by the β receptor), non-specific, or cytotoxic. Trypan blue cell counts performed both before and after incubation indicated that cell numbers decreased during incubation with β blockers (data not shown). To quantitate this effect, LDH was measured in the supernatant after incubation. Results of these experiments are shown in Fig 2. Again, timolol released significa-
not consider that high concentrations of explain the histamine liberation because we do determine the cytotoxic e. Other authors have used LDH levels to other leucocytes. Also, in previous studies blocker concentrations we used were cytotoxic LDH in the supernatant indicated that the extent, by timolol. The fact that we detected from human basophils by betaxolol and timolol. This study shows that histamine is liberated significantly less LDH than either betaxolol or metipranolol.

Discussion
This study shows that histamine is liberated from human basophils by betaxolol and metipranolol and, to a significantly lesser extent, by timolol. The fact that we detected LDH in the supernatant indicated that the β blocker concentrations we used were cytotoxic to leucocytes. This cytotoxic effect may also explain the histamine liberation because we do not consider that high concentrations of β blockers are less toxic to basophils than to other leucocytes. Also, in previous studies other authors have used LDH levels to determine the cytotoxic effects on basophils in similar test conditions.14

Betaxolol and timolol formulations are commercially available in 0.1%, 0.25%, and 0.5% concentrations and metipranolol formulations are commercially available in 0.1%, 0.3%, and 0.6% which equals approximately 2.5 × 10⁻⁴ to 2 × 10⁻³ M. The cytotoxicity found in these experiments therefore occurs at concentrations that are used in commercial formulations. However, it should be noted that, upon instillation of an eye drop, the concentration decreases by dilution with tear fluid and by binding of the β blocker to proteins in the tear fluid. Also, the contact time of the drug will be shorter than the 1 hour used in our experiments.

Nosal et al.13 investigated histamine release from isolated rat mast cells after incubation with metipranolol and several other β blockers. Metipranolol in a concentration of 10⁻³ M resulted in a 5% histamine release which is in accordance with our results. They did not test higher concentrations nor did they test for cell viability after incubation. They further found that a β blocker with a higher lipophilicity (exaprolol) induced histamine release at 10⁻¹ M which they concluded was a non-specific effect caused by perturbation of the cell membrane.

Takahashi16 tested the cytotoxicity of timolol on conjunctival cell cultures and found that timolol 0.5% (10⁻² M) did not possess any cytotoxicity. Similarly, we did not find significant cytotoxicity with timolol (10⁻² M) on leucocytes.

In our experiments metipranolol and betaxolol had a significantly higher cytotoxicity than timolol. Timolol has a considerably lower lipid solubility than betaxolol and metipranolol (Table 2).17 We feel that, because of their higher lipid solubility, betaxolol and metipranolol disturb the cell membrane integrity and that this accounts for their higher cytotoxicity. However, it should be kept in mind that eye drops need to have a certain lipid solubility to penetrate the cornea.18 In a single drop study timolol was found to reduce exercise tachycardia in contrast to metipranolol. The authors explained this by the higher lipid solubility of metipranolol permitting rapid cornea penetration and leaving less metipranolol available for systemic absorption.19

In general, patients find timolol eye drops more comfortable than metipranolol or betaxolol eye drops.20–23 Because the vehicles of the three eye drops are comparable, the low cytotoxic effect of timolol may be partly responsible for its higher degree of comfort.

This research was supported by a grant of Dr Gerhard Mann GmbH, Germany, and Tramedico BV, Netherlands.

Table 2  Lipid solubility of the tested β blockers18

<table>
<thead>
<tr>
<th>β blocker</th>
<th>Lipid solubility (log P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betaxolol</td>
<td>2.81</td>
</tr>
<tr>
<td>Metipranolol</td>
<td>2.28</td>
</tr>
<tr>
<td>Timolol</td>
<td>1.16</td>
</tr>
<tr>
<td>Carteolol</td>
<td>0.82</td>
</tr>
</tbody>
</table>


www.bjophthalmol.com